Integrating In Vitro Microtissues and In Vivo endpoints in Drug Discovery & Development

Matt Wagoner leads the Global Investigatory Toxicology network for Takeda Pharmaceuticals, where their team applys microphysiological systems (MPS) as predictive and mechanistic toxicology tools in support of discovery-phase projects. Before Takeda, Matt led the mRNA safety strategy for AstraZeneca Pharmaceuticals, and worked to develop and deploy MPS tools in support of projects. Matt has his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and bachelors in biochemistry from the University of Illinois Urbana Champaign.